

## MEDIA FACT SHEET

# Closed Loop Stimulation

BIOTRONIK strives to continuously challenge the status quo, and remains the industry's only provider of pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices with the [Closed Loop Stimulation \(CLS\)](#) rate-adaptive algorithm. Exercise, emotion and mental stress naturally cause the pulse to quicken in healthy patients. CLS is the only technology that mimics this feedback loop, adjusting cardiac device patient heart rates in response to emotional and psychological states.

### How does CLS work?

When the heart is unable to increase its rate with physical exertion (chronotropic incompetence), it cannot pump enough blood to meet the body's needs. This can lead to syncope (fainting) or other issues.

To treat these conditions, CLS translates information about myocardial contractility (the strength of the heart muscle's contraction) into a pacing rate that the patient's own cardiovascular

control system adjusts. CLS does this by monitoring and processing intracardiac impedance signals, correlated with the volume of blood in the heart's ventricles (pumping chambers).<sup>1</sup> Detectable changes in myocardial contractility are associated with the heart's response to exercise and acute mental stress.<sup>2</sup> By monitoring these changes, CLS continuously sets a pacing rate appropriate to the patient's physiologic demands at any given moment.<sup>2</sup>

### Clinical Studies and Benefits

2017's SPAIN study, published in the Journal of the American College of Cardiology, found that CLS was associated with a sevenfold reduction of syncope cases in pacemaker patients.<sup>3</sup> 2018's Rattanawong et al. meta-analysis of six studies, including SPAIN, found an 80 percent reduction in vasovagal syncope (VVS) cases in patients with CLS devices versus those receiving conventional pacing.<sup>4</sup>

### References:

1 Osswald S et al. Pacing Clin Electrophysiol. 2000, 23(10).


2 Lindovská M et al. Europace. 2012, 14(11).

3 Baron-Esquivias G, Morillo CA, Moya-Mitjans A, et al. J Am Coll Cardiol. 2017;70(14).

4 Rattanawong MD et al. Journal of Arrhythmia. 2018, 34.



## BIOTRONIK at a Glance

At **BIOTRONIK** , patient well-being is our top priority and has been for more than 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.



### Global Impact

Physicians have implanted more than 20 million BIOTRONIK devices in over 100 countries.



### Business Areas

BIOTRONIK is active in cardiac rhythm management, electrophysiology, vascular intervention and neuromodulation.



### R&D

BIOTRONIK is headquartered in Berlin and researches, develops and manufactures exclusively in the high-tech countries of Germany, Singapore, Switzerland and the United States.

All critical components are manufactured in-house to ensure uncompromised safety, the highest quality and reliability. One in five employees at Berlin headquarters work in research and development.

### Find us on Social Media

